Current Event 

Register
Overview
Day 1
Day 2
Day 3
Short Courses
Alumni
Hotel & Travel
Download Brochure
Sponsor & Exhibits 
Press Pass
Request Brochure
Archive 

 

Premier Sponsor:


Vantage Partners

 

Corporate Support Sponsor:


Integrated Project Management 

 

Media Partners:


BioCentury 

Biospace 

CanBiotech 

Current Partnering 

Pharma Connections Worldwide 

Pharmalicensing 
 

Pharmcast 

PharmaVoice 

 

Join our
Linkedin group:


Alliance Management and Business Development Network

3500+ alliance
leaders strong


Strategic Alliance Management Congress - Day 3

Conference Proceeding CD Now Available
  • Speaker Presentations
  • Poster Abstracts
  • and More!

WEDNESDAY, MAY 9


7:45 am Morning Coffee


Academic Alliances: Pharma and Diagnostics 

8:15 Chairperson’s Remarks

Teri Melese, Ph.D., Associate Professor, Medicine, Director, Business Strategy & Development, School of Medicine Dean’s Office, University of California, San Francisco

8:30 The New Face of Academia/Industry Partnerships in Biomedical Discovery and Development

Teri Melese, Ph.D., Associate Professor, Medicine, Director, Business Strategy & Development, School of Medicine Dean’s Office, University of California, San Francisco

The demand to bring transformative therapeutics to patients and the escalating costs of doing so are driving the life science industry to seek collaborations with academia to stimulate innovation. Many have made the case that the economics of innovation is a key driver for companies to open their innovation process. With drug failures and patent expirations set to erode a substantial amount of their revenues, many companies realized that they needed to look beyond their own walls for innovation. The idea that the next new approach might not come from internal research has led many companies to shift their R&D expenditures externally through collaborations with small biotechnology companies, other companies and academia. Pfizer, Merck, Roche, GlaxoSmithKline, AstraZeneca and Sanofi have all established multiyear collaborations with academic institutes across a number of therapeutic areas. Although some of these relationships are built on longstanding collaborations with academic institutions, the recent increase in the number of these collaborative relationships is part of a major change in strategic direction. These partnerships come at a crucial time for both industry and universities and have the potential to profoundly alter the means by which healthcare is delivered.

9:15 Industry-Academia Alliances – Learning from the Experts

Michal Preminger, Ph.D., M.B.A., Executive Director, Harvard Office of Technology Development

In recent years, Harvard University has prioritized industry alliances as a major strategic goal and has engaged in such alliances with multiple pharmaceutical companies. In this talk, the following topics will be discussed using specific examples and lessons learned will be shared: alliance objectives, targeted outcomes and success criteria; alliance models and structures; program and project governance and execution workflow; alliance management; and infrastructure deployed at Harvard

9:45 Incubating Technologies in Collaboration with Industry at an Academic Medical Center

Frances Toneguzzo, Ph.D., Executive Director, Research Ventures and Licensing, Partners HealthCare

This talk will discuss an incubation model to realize the full potential of cutting edge platform technologies that may not be achieved by transfer of technology under a traditional license model. Such a model brings together and leverages an academic medical institutions visionary investigators, technology, clinical expertise and intellectual property with an industry partner’s expertise in development and commercialization of products.

One such example is the partnership between Massachusetts General Hospital and Johnson & Johnson. The goal of the partnership is to collaboratively characterize microfluidic lab-on-a-chip technologies for the development of a diagnostic platform for Circulating Tumor Cell (CTC) detection. Under this partnership a translational research center (TRC) was established to function as a technology incubator housed within the hospital, and staffed by employees experienced in product development. The TRC has access to both MGH’s academic expertise, resources and talent pool and J &J’s market, regulatory and reimbursement expertise and other necessary resources including funding for this collaboration.

 

10:15 Coffee Break in the Exhibit Hall

10:45 Supporting Academic-Industry Collaborations

Seema Basu, Ph.D., Associate Director, Research Ventures & Licensing, Massachusetts General Hospital, Partners HealthCare

Given the recent trend of diverse academic-industry collaborations, this talk will cover key aspects for successfully negotiating and managing such deals, including: importance of steering committees, alliance manager, sharing resources and communications to bridge organizational cultures. Specific examples of such collaborations including CTI-Pfizer and HSCI-GSK will be discussed.

The talk will also discuss some strategies that can be incorporated into licensing agreements with early stage start-ups to facilitate technology development.

11:15 Partnering With Academia: An Industry Perspective

Annlouise Goodermuth, MBA, CA-AM, Associate Director, Alliance Management Strategy, External Innovation and Science Policy, Sanofi
 

11:45 External Innovation Network: A Model for Successful Academic-Pharma Partnering

Zafrira Avnur, Ph.D., Global Head, Academic Innovation Partnering, Roche Partnering, F. Hoffmann-La Roche Ltd

To access external innovation and to benefit from novel models of academic collaborations, Roche has launched a specific initiative called Emerging Innovations Network (EIN). Zafrira Avnur, Head of Roche Global Academic Innovation Partnering, will provide an overview of the EIN and results from the first 3 years of running the programme. The presentation will showcase successful collaborations between Roche and academia, and will provide insights into the metrics of success in the form of tangible benefits of all stakeholders. She will highlight why early-stage academic collaborations differ from traditional later-stage partnerships, and why pharma-funded research has proven to be an unsatisfactory model for harnessing innovation compared to an approach where pharma and academia work in partnership. The discussion will culminate in suggestions as to how collaborations are changing and how they can be managed to deliver more fruitful results.

12:15 Luncheon Presentations or Lunch on Your Own

(Sponsorship Opportunities Available)

 

» 1:45 CASE STUDY 

Arctic Dx and National Jewish Health Diagnostics Partnership in the Fight Against Age-Related Macular Degeneration 

Preveen Ramamoorthy, Ph.D., Director, Molecular Diagnostics Advanced Diagnostic Laboratories, Assistant Professor, Department of Medicine, National Jewish Health 

Brent Zanke, M.D., CMO, Arctic Dx 


 


» 2:30 EXPERT PANEL 

Sponsored & Collaborative Research: Managing Relationships in Deals between Universities/Research Institutions and Industry

Moderator: Steven M. Ferguson, CLP, Deputy Director, Licensing & Entrepreneurship, Office of Technology Transfer, National Institutes of Health

This interactive session will focus on the aspects of managing the expectations & interests of universities/research institutions and industry in negotiating and administering sponsored and collaborative research agreements. The panel includes speakers with substantial experience in sponsored and collaborative research agreements from the perspectives of the university/research institution, high tech and life sciences companies, and outside counsel. The session will cover a variety of topics that can often lead to misunderstandings in university – industry research collaborations: retention of IP rights by the university/research institution and granted to the research sponsor; sharing licensing revenues; the right to the free publication of results; and universities’/research institutions’ interests in making inventions available under conditions that will promote their effective development and utilization in the public interest. Additional topics will include who owns the IP; IRS issues; background rights; patent prosecution; patent enforcement; trade secrets; sharing of materials and development and commercialization.

Panelists:

Ellen Purpus, Ph.D., Director, Office of Technology Transfer, The Children's Hospital of Philadelphia

Annlouise Goodermuth, MBA, CA-AM, Associate Director, Alliance Management Strategy, External Innovation and Science Policy, Sanofi 

Sanjeev Munshi,Director,  Licensing & External Research, Merck
 


3:30 Close of Strategic Alliance Management Congress

 

Day 1Day 2 | Day 3 


By Series:
By Region: